The chief executive’s choice of words on Friday was telling. “The obesity market is not a zero-sum game,” Mike Doustdar told Reuters, reaching for an analogy from the company’s own history — a dozen insulin brands once coexisted, so why not the same for GLP-1 therapies? It is the kind of reassurance a company typically […]
The post